TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06375044: Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 130 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,884,960

Rescue Site Savings

+$1,256,640

Unlock Full NCT06375044 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06375044 Rescue Dossier →